Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2024-11-20 00:00:00 ET · period of report 2024-11-19 · accession 0000950170-24-129455 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2024-11-20 | 2024-11-19 | BBIO | Kumar Neil | CEO, Dir | S - Sale | $22.42 | -27.4K | 4.90M | -0.6% | -$613.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-19 | S | D | 25,514 | $22.39 | 4,899,318 | D | — | — | (F2) Represents the weighted average sale price of the shares sold ranging from $21.73 to $22.72 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2024-11-19 | S | D | 1,875 | $22.76 | 4,897,443 | D | — | — | (F3) Represents the weighted average sale price of the shares sold ranging from $22.73 to $22.92 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |